New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
06:20 EDTARIA, GILD, INFIGilead seeks more blood cancer drug deals, Bloomberg reports
Gilead Sciences (GILD) has spent $1.2B in two years to buy blood cancer drugs, and wants more, reports Bloomberg. Treatment for leukemia and other blood cancers is one of the fastest growing markets for cancer drugs. Gilead COO John Milligan said the company is eyeing possible new deals. They could include Ariad Pharmaceuticals (ARIA) and Infinity Pharmaceuticals (INFI), said Raghuram Selvaraju, at Aegis Capital Corp. Reference Link
News For GILD;ARIA;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 11, 2014
07:54 EDTGILDGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
06:14 EDTARIAARIAD downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
December 10, 2014
15:59 EDTGILDGilead sued by SEPTA over price of Hep C drug Sovaldi, WSJ reports
Subscribe for More Information
December 9, 2014
11:31 EDTINFIInfinity Pharmaceuticals reports results from Phase 1 study of duvelisib
Infinity Pharmaceuticals reported updated data from a Phase 1 monotherapy study of duvelisib, an inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma, a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72%, including a 33% complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma.
09:38 EDTGILDActive equity options trading
Subscribe for More Information
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
08:38 EDTGILDGilead price target raised to $130 from $110 at Argus
Subscribe for More Information
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
December 8, 2014
16:00 EDTGILDOptions Update; December 8, 2014
Subscribe for More Information
10:47 EDTINFIInfinity reports updated Phase 1 data from duvelisib study, says well tolerated
Subscribe for More Information
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
December 7, 2014
14:31 EDTINFIInfinity Pharmaceuticals to hold a luncheon and data presentation meeting
Subscribe for More Information
December 5, 2014
09:36 EDTGILDActive equity options trading
Subscribe for More Information
07:37 EDTGILDGilead price target raised to $121 from $110 at JPMorgan
JPMorgan raised its price target for Gilead shares to $121 saying the company's potential cash flow generation is "immense" and provides "significant strategic flexibility." The firm estimates Gilead can generate more than $30B in cash in the next two years and $80B-plus over the next five years. It keeps an Overweight rating on the stock.
December 4, 2014
10:08 EDTINFIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:01 EDTGILDVA negotiated $594 per dose price for Gilead HCV treatment
A Veterans Health Administration official told a Senate committee yesterday that Veterans' Affairs has "moved rapidly to deploy new, more effective, less toxic HCV treatments and has been able to negotiate significant discounts for these newer therapies." The agency negotiated a price of $594 per dose for Gilead's (GILD) Hepatitis C virus drug Sofosbuvir, below the commercial price of $1,000 per dose, VHA Chief Consultant for Pharmacy Benefits Management Michael Valentino told the Senate's Committee on Veterans' Affairs. The agency also received a $413 per dose price for Johnson & Johnson's (JNJ) Simeprevir, below the commerical price of $790. The VA has approximately 174,000 veterans in care with HCV, making it the largest single HCV provider in the U.S., Valentino pointed out. He added, "Like the rest of the country, VA has treated only a portion of Veterans for HCV because treatment and cures have been difficult to achieve due to low efficacy and high toxicity of standard drug therapies." Reference Link
06:32 EDTINFIInfinity Pharmaceuticals upgraded at Credit Suisse
Subscribe for More Information
06:05 EDTINFIInfinity Pharmaceuticals upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use